Literature DB >> 31077394

Extranodal extension is a strong prognosticator in HPV-positive oropharyngeal squamous cell carcinoma.

Eric Bauer1, Angela Mazul1, Rebecca Chernock2, Jason Rich1, Ryan S Jackson1, Randal Paniello1, Patrik Pipkorn1, Peter Oppelt3, Hiram Gay4, Mackenzie Daly4, Samir El-Mofty2, Wade Thorstad4, Douglas Adkins3, Jose Zevallos1.   

Abstract

OBJECTIVE: To comprehensively examine the prognostic significance of extranodal extension (ENE) in human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV-positive OPSCC).
METHODS: Retrospective cohort of cases diagnosed with HPV-positive OPSCC from 2010 to 2015 in the National Cancer Database. Inclusion of all OPSCC HPV-positive cases with appropriate International Classification of Diseases-0-3 codes that received surgery with a neck dissection. Univariate and multivariable analyses were conducted. Hazard ratios (HR) for the independent effects of ENE and N stage on overall survival were estimated by Cox proportional hazards regression.
RESULTS: Cases that were ENE-negative had the highest 5-year survival (92.6%; 95% confidence interval [CI]: 90.5%-94.7%). ENE-positive cases had the lowest 5-year survival (84.0%; 95% CI: 80.7%-87.4%). After adjusting for confounding variables, ENE-positivity was associated with almost twice the hazard of death (HR = 1.90; 95% CI: 1.35-2.67) compared to ENE-negative cases. Nodal (N) category 1, ENE-positive status was associated with an increased risk of death (HR = 1.88; 95% CI: 1.26-2.80) compared with N1, ENE-negative status. Compared to N1/ENE-negative cases, N2/ENE-positive cases had the poorest survival (HR: 2.93; 95% CI: 1.94-4.43). Both microscopic and macroscopic ENE were associated with worse outcomes compared to node-positive/ENE-negative status.
CONCLUSION: The implementation of the American Joint Committee on Cancer 8th edition staging system provides a much-improved framework to develop and discuss treatment plans for HPV-positive OPSCC. We feel that careful consideration should be given to the importance of ENE in patients with HPV-positive OPSCC. LEVEL OF EVIDENCE: 4 Laryngoscope, 130:939-945, 2020.
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  AJCC staging; HPV-positive; extranodal extension; head and neck; neck; neck dissection; oropharyngeal squamous cell carcinoma; oropharynx

Mesh:

Year:  2019        PMID: 31077394     DOI: 10.1002/lary.28059

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  13 in total

1.  De-Escalated Adjuvant Therapy After Transoral Robotic Surgery for Human Papillomavirus-Related Oropharyngeal Carcinoma: The Sinai Robotic Surgery (SIRS) Trial.

Authors:  Brett A Miles; Marshall R Posner; Vishal Gupta; Marita S Teng; Richard L Bakst; Mike Yao; Kryzsztof J Misiukiewicz; Raymond L Chai; Sonam Sharma; William H Westra; Seunghee Kim-Schulze; Bheesham Dayal; Stanislaw Sobotka; Andrew G Sikora; Peter M Som; Eric M Genden
Journal:  Oncologist       Date:  2021-03-18

Review 2.  Critical Changes in the Staging of Head and Neck Cancer.

Authors:  Christine M Glastonbury
Journal:  Radiol Imaging Cancer       Date:  2020-01-31

Review 3.  De-Escalation Strategies for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma-Where Are We Now?

Authors:  Jennifer A Silver; Sena Turkdogan; Catherine F Roy; Thavakumar Subramaniam; Melissa Henry; Nader Sadeghi
Journal:  Curr Oncol       Date:  2022-05-18       Impact factor: 3.109

4.  EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling.

Authors:  Shinya Sato; Suhas Vasaikar; Adel Eskaros; Young Kim; James S Lewis; Bing Zhang; Andries Zijlstra; Alissa M Weaver
Journal:  JCI Insight       Date:  2019-12-05

5.  Low-risk human papilloma virus positive oropharyngeal cancer with one positive lymph node: Equivalent outcomes in patients treated with surgery and radiation therapy versus surgery alone.

Authors:  Reilly A Sample; Carey Burton Wood; Angela L Mazul; Thomas F Barrett; Randal C Paniello; Jason T Rich; Stephen Y Kang; Jose Zevallos; Mackenzie D Daly; Wade L Thorstad; Stephanie Y Chen; Patrik Pipkorn; Ryan S Jackson; Sidharth V Puram
Journal:  Head Neck       Date:  2021-02-15       Impact factor: 3.821

Review 6.  Deintensification of Adjuvant Treatment After Transoral Surgery in Patients With Human Papillomavirus-Positive Oropharyngeal Cancer: The Conception of the PATHOS Study and Its Development.

Authors:  Sarah Hargreaves; Matthew Beasley; Chris Hurt; Terry M Jones; Mererid Evans
Journal:  Front Oncol       Date:  2019-10-01       Impact factor: 6.244

7.  Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell Carcinomas.

Authors:  Pooja Vijayvargiya; Sumita Trivedi; Manali Rupji; Haocan Song; Yuan Liu; Renjian Jiang; Azeem S Kaka; Georgia Z Chen; William Stokes; Conor Steuer; Dong M Shin; Jonathan J Beitler; Mihir R Patel; Ashley Aiken; Nabil F Saba
Journal:  Oncologist       Date:  2022-02-03

8.  Differential expression of podoplanin in metastatic lymph node is associated with extranodal extension in oropharyngeal cancer.

Authors:  Hye Ran Lee; Jin Roh; Ga Young Gu; Ju Ho Lee; Yoo Seob Shin; Jeon Yeob Jang; Chul-Ho Kim
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.379

9.  [De-escalation of adjuvant radiotherapy after transoral surgery of HPV-associated oropharyngeal cancer: results of the E3311 trial].

Authors:  Alexander Rühle; Nils H Nicolay
Journal:  Strahlenther Onkol       Date:  2022-02-08       Impact factor: 3.621

Review 10.  HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management.

Authors:  Matt Lechner; Jacklyn Liu; Liam Masterson; Tim R Fenton
Journal:  Nat Rev Clin Oncol       Date:  2022-02-01       Impact factor: 65.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.